We initiate coverage of Mauna Kea Technologies with an OUTPERFORM recommendation and a target price of €4.10 per share. Mauna Kea is a commercial stage medical device company headquartered in Paris, France. The company's main product, Cellvizio, is a market-leading confocal laser endomicroscopy system used for in-depth analysis of cellular microstructure, facilitating the real-time identification of pre-cancerous lesions in anatomical tracts such as the gastrointestinal and pulmonary tra
12 Jul 2018
Optical biopsies for increased diagnostic accuracy
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Optical biopsies for increased diagnostic accuracy
Mauna Kea Technologies SA Class O (0P5I:LON) | 0 0 0.2% | Mkt Cap: 75.0m
- Published:
12 Jul 2018 -
Author:
Martin Brunninger -
Pages:
37
We initiate coverage of Mauna Kea Technologies with an OUTPERFORM recommendation and a target price of €4.10 per share. Mauna Kea is a commercial stage medical device company headquartered in Paris, France. The company's main product, Cellvizio, is a market-leading confocal laser endomicroscopy system used for in-depth analysis of cellular microstructure, facilitating the real-time identification of pre-cancerous lesions in anatomical tracts such as the gastrointestinal and pulmonary tra